SQZ Biotechnologies Company (SQZB)
OTCMKTS: SQZB · Delayed Price · USD
0.0499
0.00 (0.00%)
May 1, 2024, 12:00 AM EDT - Market open
SQZB Revenue
SQZ Biotechnologies Company had revenue of $18.61M in the twelve months ending March 31, 2023, down -24.08% year-over-year. In the year 2022, SQZ Biotechnologies Company had annual revenue of $21.48M, a decrease of -20.74%.
Revenue (ttm)
$18.61M
Revenue Growth
-24.08%
P/S Ratio
0.08
Revenue / Employee
$351,132
Employees
53
Market Cap
1.47M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 21.48M | -5.62M | -20.74% |
| Dec 31, 2021 | 27.10M | 6.10M | 29.05% |
| Dec 31, 2020 | 21.00M | 889.00K | 4.42% |
| Dec 31, 2019 | 20.11M | 7.44M | 58.73% |
| Dec 31, 2018 | 12.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 371.62B |
| Johnson & Johnson | 85.16B |
| Merck & Co. | 60.12B |
| AbbVie | 54.32B |
| Novartis AG | 49.92B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.86B |
| Abbott Laboratories | 40.11B |
SQZB News
- 2 months ago - STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company - Business Wire
- 2 months ago - Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders - Business Wire
- 6 months ago - SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 6 months ago - SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 9 months ago - SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates - Business Wire
- 10 months ago - SQZ Biotechnologies Provides Update on Collaboration with Roche - Business Wire
- 10 months ago - NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ) - Business Wire
- 11 months ago - SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split - Business Wire